We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 9 for:    "Dent disease"

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

This study is currently recruiting participants.
Verified August 2017 by John Lieske, Mayo Clinic
Sponsor:
ClinicalTrials.gov Identifier:
NCT02016235
First Posted: December 19, 2013
Last Update Posted: August 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
John Lieske, Mayo Clinic
  Purpose
Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Condition Intervention Phase
Dent Disease Drug: Phosphorus Supplement Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Role Of Phosphorus And FGF 23 In Patients With Dent Disease

Resource links provided by NLM:


Further study details as provided by John Lieske, Mayo Clinic:

Primary Outcome Measures:
  • Change in 24 hr urine and serum after 2 weeks of phosphorus supplementation [ Time Frame: 6 months ]
    This study will measure the changes in a 24 hr urine supersaturation and serum after phosphorus is taken for two weeks to decrease stone formation


Estimated Enrollment: 40
Study Start Date: September 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dent Disease patients
A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria: 1. Hypercalriuria, 2. Kidney Stones, 3. Nephrocalcinosis, 4. Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with X-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.
Drug: Phosphorus Supplement
250 mg po qid
Other Name: K-phos neutral
Experimental: hypercalciuria w/ phosphate leak
A. Male patients >18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (>250 mg/24 hrs); 3) renal phosphate leak (TMP/GFR <2.07 mg/dl)
Drug: Phosphorus Supplement
250 mg po qid
Other Name: K-phos neutral
Experimental: hypercalciuria w/out phosphate leak
A. Male patients >18 years old will be recruited from the stone clinics at Mayo Clinic and NY Harbor VA Medical Center B. Eligibility Criteria include: 1) History of a symptomatic calcium oxalate or calcium phosphate stone; 2) hypercalciuria (>250 mg/24 hrs); 3) (TMP/GFR <2.07 mg/dl)
Drug: Phosphorus Supplement
250 mg po qid
Other Name: K-phos neutral

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients will be recruited from those in the RKSC Dent Registry

    Diagnostic criteria for Dent disease include:

    A. 1. LMWP (at least 5 times above the upper limit of normal) and at least 1 of the following criteria: 1. Hypercalciuria, 2. Kidney stones, 3. Nephrocalcinosis, 4. Hypophosphatemia, 5. Renal phosphate leak, 6. Aminoaciduria, 7. Glucosuria without diabetes mellitus, 8. Hematuria, 9. Renal insufficiency, 10. Family history with x-linked inheritance or B. 1 of the above criteria (1-9) and confirmed genetic mutation of CLCN5 or OCRL1.

  2. Idiopathic calcium nephrolithiasis with renal phosphate leak

    1. Male patients > 18 years old
    2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR <2.07 mg/dl)
  3. Idiopathic calcium nephrolithiasis without renal phosphate leak

    1. Male patients > 18 years old
    2. History of symptomatic calcium oxalate or calcium phosphate stone, hypercalciuria (>250 mg/24 hrs), renal phosphate leak (TMP/GFR <2.07 mg/dl)

Exclusion Criteria:

  1. Exclusion for Dent disease include: primary or secondary hyperparathyroidism, hyperthyroidism, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study.
  2. Exclusion criteria for calcium stone formers include: primary or secondary hyperparathyroidism, hyperthyroidism, estimated GFR <40 ml/mn/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study.
  3. Exclusion criteria include history of symptomatic or asymptomatic kidney stone disease; primary or secondary hyperparathyroidism; estimated GFR <40 ml/min/1.73m2, chronic diarrhea states; intake of thiazide diuretics, glucocorticoids, or estrogens within one month of the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02016235


Contacts
Contact: Barbara M Seide 800-270-4637 rarekidneystones@mayo.edu
Contact: Alicia M Meek 800-270-4637 rarekidneystones@mayo.edu

Locations
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Barbara Siede         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Barbara M Seide    800-270-4637    rarekidneystones@mayo.edu   
Contact: Alicia M Meek    800-270-4637    rarekidneystones@mayo.edu   
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: John C Lieske, M.D. Mayo Clinic
  More Information

Responsible Party: John Lieske, M.D., Mayo Clinic
ClinicalTrials.gov Identifier: NCT02016235     History of Changes
Other Study ID Numbers: 13-004774
First Submitted: December 6, 2013
First Posted: December 19, 2013
Last Update Posted: August 7, 2017
Last Verified: August 2017

Keywords provided by John Lieske, Mayo Clinic:
Dent
Dents
Dent Disease
Phosphorus Supplements
FGF 23

Additional relevant MeSH terms:
Dent Disease
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Metabolic Diseases